CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

This study is testing a new CAR-T cell therapy called Senza5 CART5 for people with certain types of T-cell lymphoma (a cancer of immune cells) that have come back or stopped responding to treatment. This approach deletes a protein (CD5) from the therapy cells so they don't accidentally attack each other. **You may be eligible if...** - You have a confirmed diagnosis of relapsed or treatment-resistant CD5-positive T-cell lymphoma - Your cancer cells show at least 50% CD5 expression - You have received at least one prior treatment - You are in reasonably good physical condition **You may NOT be eligible if...** - You have leukemic (blood-circulating) forms of T-cell cancer rather than lymphoma - Your organs are not healthy enough to tolerate the treatment - You are pregnant or breastfeeding - You have active infections that are not under control Talk to your doctor to see if this trial is right for you.